The growing pipeline of gene therapy treatments for CNS disorders is expected to drive the growth of the gene therapy in CNS disorder market in the coming years. According to a report by Future Market Insights, the global gene therapy in CNS disorder market is expected to grow at a compound annual growth rate (CAGR) of 30% from 2023 to 2033.
One of the key drivers of this growth is the increasing prevalence of CNS disorders, particularly neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. As the global population ages, the incidence of these disorders is expected to increase, creating a significant healthcare burden and driving demand for effective treatments.
In addition, the growing investment in gene therapy research and development is expected to accelerate the development of new treatments for CNS disorders. The FDA and other regulatory agencies have established expedited pathways for the review and approval of gene therapy treatments, allowing for faster development and commercialization of these treatments.
Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16744
Key Takeaways from the Market Study
- From 2018 to 2022, the Gene Therapy in CNS Disorder market grew at a CAGR of 19%.
- The global Gene Therapy in CNS Disorder market is expected to grow with a 30% CAGR during 2023 to 2033.
- As of 2033, the Gene Therapy in CNS Disorder Market is expected to reach US$ 113.04 Billion.
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 40% market share for the Gene Therapy in CNS Disorder market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Gene Therapy in CNS Disorder.” says an FMI analyst
Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16744
Market Competition
Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.
- In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.
In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Gene Therapy in CNS Disorder market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Indication, Type, End-users & Region.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16744
Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey
Indication:
- Alzheimer’s Disease
- Huntington’s Disease
- Parkinson’s Disease
- Batten Disease
Type:
- Ex Vivo
- In Vivo
End User:
- Hospitals
- Speciality Clinics
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs